phrykt

Scholar Rock Holding Corp (SRRK): who owns it and who trades it

As of Nov 16, 2026, SRRK insiders reported 37 open-market sales worth $19.4M and 6 purchases worth $12M in the last 12 months, with 41% of the sale value made under pre-set 10b5-1 plans. The largest seller was Mo Qatanani (CHIEF SCIENTIFIC OFFICER), with $8.6M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Scholar Rock Holding

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns SRRK

305 funds and institutions reported SRRK shares worth $7.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 15.7%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)15.7%
Siren, L.L.C.8.3%
BlackRock, Inc.8.3%
Samsara Biocapital, LLC6.0%
T. Rowe Price Associates5.9%
Wellington Management Group LLP5.9%
Orbis Allan Gray Ltd5.2%
Vanguard Capital Management LLC4.2%
State Street Corp4.1%
Redmile Group, LLC3.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)18.00M15.66%$990M+4%
Siren, L.L.C.9.58M8.33%$527M-12%
BlackRock, Inc.9.49M8.26%$522M+27%
Samsara Biocapital, LLC6.90M6.00%$379MNo change
T. Rowe Price Associates6.79M5.91%$374M+9%
Wellington Management Group LLP6.73M5.86%$370M+0%
Orbis Allan Gray Ltd5.93M5.16%$326M+42%
Vanguard Capital Management LLC4.77M4.15%$262M+23%
State Street Corp4.73M4.12%$260M+17%
Redmile Group, LLC4.31M3.75%$237M-52%
Norges Bank2.77M2.41%$152M–
Geode Capital Management, LLC2.75M2.40%$151M+28%
Massachusetts Financial Services Co2.61M2.27%$143M–
Bellevue Group AG2.45M2.13%$135M-32%
Jennison Associates LLC2.36M2.05%$130M-29%
Jupiter Topco LLC2.24M1.95%$123M–
Hood River Capital Management LLC2.22M1.94%$122M+9%
Driehaus Capital Management LLC2.21M1.92%$121M+15%
Eventide Asset Management, LLC2.11M1.84%$116M-4%
Polar Capital Holdings Plc1.88M1.64%$103M-5%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, SRRK insiders reported $12M of open-market purchases and $19.4M of sales. 41% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$12M
6 trades, 1 people
Sales, 12 months
$19.4M
37 trades, 13 people
Sales under a 10b5-1 plan
41%
Share of sale value
Latest trade
Oct 26, 2026
Filed Oct 27, 2026

Purchases and sales by month

$12M$12MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 26, 2026Srinivas AkkarajuDirectorPurchase48,988$41.59$2MForm 4
Oct 26, 2026Srinivas AkkarajuDirectorPurchase97,982$41.59$4.1MForm 4
Oct 23, 2026Srinivas AkkarajuDirectorPurchase47,000$41.31$1.9MForm 4
Oct 23, 2026Srinivas AkkarajuDirectorPurchase94,000$41.31$3.9MForm 4
Oct 23, 2026Srinivas AkkarajuDirectorPurchase500$41.82$20.9KForm 4
Oct 23, 2026Srinivas AkkarajuDirectorPurchase1,000$41.82$41.8KForm 4
Jul 1, 2026Jeffrey S. FlierDirectorSale1,568$53.53$83.9KForm 4
Jul 1, 2026Jeffrey S. FlierDirectorSale15$54.88$823Form 4
Jul 1, 2026Jeffrey S. FlierDirectorSale1,470$54.24$79.7KForm 4
Jul 1, 2026Michael GilmanDirectorSale43$54.81$2.4KForm 4
Jul 1, 2026Michael GilmanDirectorSale1,346$53.54$72.1KForm 4
Jul 1, 2026Michael GilmanDirectorSale1,155$54.23$62.6KForm 4
Jul 1, 2026Kristina BurowDirectorSale2,105$53.49$113KForm 4
Jul 1, 2026Kristina BurowDirectorSale948$54.28$51.5KForm 4
Jul 1, 2026Joshua ReedDirectorSale2,105$53.50$113KForm 4
Jul 1, 2026Katie PengDirectorSale2,988$53.56$160KForm 4
Jul 1, 2026Katie PengDirectorSale21$54.96$1.2KForm 4
Jul 1, 2026Katie PengDirectorSale2,437$54.25$132KForm 4
Apr 16, 2026Keith WoodsChief Operating OfficerSale10,220$49.57$507KForm 4
Apr 16, 2026Akshay VaishnawPresidentSale12,246$49.57$607KForm 4
Apr 16, 2026Vikas SinhaCFOSale10,410$49.57$516KForm 4
Apr 16, 2026David HallalCEOSale30,615$49.57$1.5MForm 4
Feb 23, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale plan7,427$46.94$349KForm 4
Feb 23, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale plan200$48.48$9.7KForm 4
Feb 23, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale plan857$47.86$41KForm 4
Feb 17, 2026Jing L. MarantzCHIEF MEDICAL OFFICERSale4,157$46.53$193KForm 4
Feb 17, 2026Junlin HoGENERAL COUNSELSale9,580$46.53$446KForm 4
Feb 17, 2026Caryn ParlavecchioCHROSale9,035$46.53$420KForm 4
Feb 17, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale7,989$46.53$372KForm 4
Jan 22, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale plan2,119$45.87$97.2KForm 4
Jan 22, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale plan12,779$46.85$599KForm 4
Jan 16, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale8,406$44.48$374KForm 4
Jan 16, 2026Caryn ParlavecchioCHROSale6,600$44.48$294KForm 4
Jan 16, 2026Jing L. MarantzCHIEF MEDICAL OFFICERSale5,798$44.48$258KForm 4
Jan 16, 2026Junlin HoGENERAL COUNSELSale8,016$44.48$357KForm 4
Jan 14, 2026Mo QatananiCHIEF SCIENTIFIC OFFICERSale plan13,112$45.20$593KForm 4
Jan 13, 2026Vikas SinhaCFOSale16,755$42.70$715KForm 4
Jan 13, 2026Keith WoodsChief Operating OfficerSale16,746$42.70$715KForm 4
Jan 13, 2026Akshay VaishnawPresidentSale20,438$42.70$873KForm 4
Jan 13, 2026David HallalCEOSale57,450$42.70$2.5MForm 4
Dec 16, 2025Katie PengDirectorSale plan726$43.88$31.9KForm 4
Dec 16, 2025Katie PengDirectorSale plan280$44.63$12.5KForm 4
Dec 4, 2025Mo QatananiCHIEF SCIENTIFIC OFFICERSale plan136,462$45.21$6.2MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Srinivas AkkarajuDirector$12M–Oct 26, 2026
Mo QatananiCHIEF SCIENTIFIC OFFICER–$8.6MFeb 23, 2026
David HallalChief Executive Officer, Director–$4MApr 16, 2026
Akshay VaishnawPresident of R&D, Director–$1.5MApr 16, 2026
Vikas SinhaChief Financial Officer–$1.2MApr 16, 2026
Keith WoodsChief Operating Officer–$1.2MApr 16, 2026
Junlin HoGENERAL COUNSEL–$802KFeb 17, 2026
Caryn ParlavecchioCHRO–$714KFeb 17, 2026
Jing L. MarantzCHIEF MEDICAL OFFICER–$451KFeb 17, 2026
Katie PengDirector–$338KJul 1, 2026
Jeffrey S. FlierDirector–$164KJul 1, 2026
Kristina BurowDirector–$164KJul 1, 2026
Michael GilmanDirector–$137KJul 1, 2026
Joshua ReedDirector–$113KJul 1, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

SRRK short interest

High short interest. 19.3% of SRRK shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 50%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 23.48M SRRK shares were sold short, 19.3% of the shares outstanding, up 5.9% from the report before. At the average daily volume of 1.73M shares, buying them all back would take about 13.6 trading days (days to cover).

Shares short, % of all shares

19.3%May 15Oct 3020.1%

Days to cover

13.6May 15Oct 3021.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202623.48M19.28%+6%1.73M13.6
Oct 15, 202622.18M18.21%-2%1.74M12.7
Sep 30, 202622.72M18.66%+17%2.44M9.3
Sep 15, 202619.41M15.94%+8%1.79M10.8
Aug 31, 202618.01M14.79%-1%1.17M15.4
Aug 14, 202618.22M14.96%+3%919,25319.8
Jul 31, 202617.67M15.38%+0%1.09M16.2
Jul 15, 202617.60M15.32%-4%1.09M16.1
Jun 30, 202618.38M15.99%+10%2.55M7.2
Jun 15, 202616.73M14.56%+2%1.04M16.2
May 29, 202616.43M14.30%+5%1.21M13.6
May 15, 202615.66M13.63%+5%1.31M11.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Scholar Rock Holding company events

Scholar Rock Holding filed 12 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.

  1. Nov 10, 2026AgreementScholar Rock Holding Corporation’s wholly owned subsidiary Scholar Rock Inc. entered into an asset purchase agreement with BioNTech US Inc. pursuant to which Scholar Rock agreed to sell a Rare Pediatric Disease Priority Review Voucher to Buyer. Filing
  2. Sep 15, 2026AnnouncementShared information with investors. Filing
  3. Sep 14, 2026AnnouncementThe Company announced that the FDA has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of SMA in adults and children 2 years of age and older who are currently receiving a survival SMN2 targeted treatment. Filing
  4. Aug 6, 2026AnnouncementAs previously disclosed, Scholar Rock Holding Corporation entered into an Open Market Sale Agreement SM, dated November 14, 2022, with Jefferies LLC relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its… Filing
  5. Aug 6, 2026ResultsReleased financial results. Filing
  6. Jun 5, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Mar 31, 2026AnnouncementThe Company announced that it resubmitted its BLA to the FDA for apitegromab for the treatment of children and adults with SMA. The Company anticipates FDA acceptance within 30 days and a review period of up to six months from the date of resubmission, with a Prescription Drug User Fee Act action… Filing
  9. Mar 3, 2026ResultsAmended an earlier report. Released financial results. Filing
  10. Mar 3, 2026ResultsReleased financial results. Filing
  11. Jan 12, 2026AnnouncementThe Company will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026. Filing
  12. Dec 2, 2025AnnouncementAs previously disclosed, on October 10, 2025, Catalent Indiana, LLC (part of Novo Nordisk) informed Scholar Rock Holding Corporation that, following the Form FDA 483 issued to Catalent Indiana, LLC on July 14, 2025, the U.S. Food and Drug Administration determined that the inspection classification… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Scholar Rock Holding financials

Famous investors that hold SRRK

5 of the 50 well-known investors we track reported holding SRRK in their latest 13F filing. The largest position is Ken Griffin's, worth $101M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.09M$101M0.1%+531%
Steve Cohen · Point72 Asset ManagementQ3 2026437,363$21.1M0.0%New
Ken Fisher · Fisher Asset ManagementQ3 2026261,849$12.7M0.0%-40%
Jim Simons · Renaissance TechnologiesQ3 202662,500$3M0.0%-32%
Israel Englander · Millennium ManagementQ3 202620,566$994K0.0%+14%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SRRK in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.8%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A4.8%
Nov 16, 2026Wellington Management Group LLP13G/A7.2%
Nov 16, 2026Wellington Management Group LLP13G/A7.2%

Questions about Scholar Rock Holding Corp (SRRK) stock

Who owns the most SRRK stock?

The largest reported owner of Scholar Rock Holding Corp (SRRK) is FMR LLC (Fidelity), with 15.7% of the company. In total, 305 funds and institutions reported holding SRRK at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are SRRK insiders buying or selling?

In the last 12 months, SRRK insiders reported 6 open-market purchases worth $12M and 37 sales worth $19.4M. The latest trade was on Oct 26, 2026. See every trade.

What is the short interest in SRRK?

As of Oct 30, 2026, 23.48M SRRK shares were sold short, 19.3% of the shares outstanding, up 5.9% from the report before. At the average daily volume of 1.73M shares, buying them all back would take about 13.6 trading days (days to cover). See the history.

Which famous investors hold SRRK?

5 of the 50 well-known investors we track reported SRRK in their latest 13F filing, including Ken Griffin, Steve Cohen, Ken Fisher. The largest position is worth $101M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.